Agenda

Day One - Wednesday 10 May 2006

09:00 Registration opens

10:30 Welcome & Introduction

10:45 What's the Big Deal?

Striking the right balance for your biotech business. Cambridge biotech companies share the platform with their big pharma partners to tell us about their recent collaborations. Discover their deal making motives and tactics.

Astex Therapeutics Ltd	Dr Martin Buckland, Chief Business Officer
Novartis Pharmaceuticals Corporation	Dr Theresa Stevens, VP & Global Head, BD&L General Medicines
Arakis Ltd	Dr Julian Gilbert, Commercial Director
Paradigm Therapeutics Ltd	Dr Barry Kenny, Commercial Director
Cambridge Antibody Technology Ltd	Dr Peter Chambré, CEO
Cambridge Antibody Technology Ltd	Dr Richard Mason, Senior VP Business Development
Isogenica Ltd	Dr Kevin FitzGerald, CE

12:15 Lunch

12:30 - 13:30 UKTI Case Study Workshop - James Watson Room

13:45 Keynote speakers

Chaired by Paul Edwards CEO Ruston Poole International

International Myeloma Foundation (UK)	Eric Low, Chief Executive
The everyday challenges faced by the biotech industry can often seem overwhelming, so parhaps it's not surprising that we sometimes lose sight of the beneficiary of our efforts - the patient. Eric Low reminds us what we are all striving to achieve.
BioCatalyst International	Sheridan Snyder, OBE, LLB (Hon.), Chairman
A veteran entrepreneur, Sherry Snyder has created 13 companies and organisations since 1964. He is currently Chairman/CEO of BioCatalyst International which creates biotech start-up companies. Snyder has been active in biotechnology since 1981 when he founded Genzyme; his most recent biotech success being Upstate Group which was sold to Serologicals in 2004.
Burrill & Company	Dr G Steven Burrill, CEO
Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 35 years. An early pioneer, Mr Burrill is one of the original architects of the industry and one of its most avid and sustained developers.

15:15 Afternoon Break

16:00 Emerging Markets

Malcolm Skingle of GSK discusses the opportunities and challenges of doing business in emerging merkets with senior executives who have first hand experience of these new geographies.

GlaxoSmithKline (GSK)	Dr Malcolm Skingle, Director, European Academic Liaison
Cambridge Theranostics Ltd	Dr Ivan Petyaev, Chief Medical and Scientific Officer
Cambridge Biostability Ltd	Dr Paul Rewrie, Commercial Director
Oriundo (Brazil)	John Anderson, Brazil Partner
British Trade Office, Bangalore	Mamtha Sharma, Senior Trade & Investment Advisor, India

17:20 ERBI Update

17:40 Been There, Done That

In this "Parkinson"-style interview, Mark Treherne talks to Simon Best, Gordon Smith Baxter and Ian Kent to find out how they made it to the top.

Senexis Ltd	Dr Mark Treherne,CEO
BIA	Dr Simon Best, Chairman
Ian Kent	Serial Entrepreneurial Chairman
Biowisdom Ltd	Dr Gordon Smith Baxter, CEO

19:00 Networking dinner with a difference
at the fabulous new Nucleus Centre

Day Two - Thursday 11 May 2006

08.00 Registration opens

08:45 Session starts

08:45 Raising Smart Money

More and more entrepreneurs are exploring additional sources of funding to traditional venture capital. Government grants, corporate venture funds and pharma deals - is this the "smart" way to raise funds in the current funding climate?

AstraZeneca	Dr Christopher Reilly, VP, Head of Global Project Evaluation
Acambis plc	Mr Gordon Cameron, CEO
Genentech	Dr Jonathon Lewis, Associate Director, Business Development

09:45 Phase III and Beyond

Follow the progress of Cambridge companies along the development pipeline to Phase III. Learn from those who have made that journey and find out how they rose to the challenge.

BTG plc	Dr Louise Makin, CEO
Pharmaprojects	Jan Beal, Biotech Editor
Alizyme plc	Dr Richard Palmer, CEO
CeNeS plc	Simon Kerr, COO

10:40 Morning Break

11:25 Marriages are made in heaven - are M&As?

Chaired by Dr Andy Richards, Biotech Entrepreneur
Cambridge is witnessing unprecedented levels of M&A activity. In this session, we gain unique insights into M&A from those who have recently acquired or been acquired.

Biovitrum plc	Dr Johan Kördel, Co-Founder
Galapagos nv	Onno van de Stolpe, CEO
Shire Pharmaceuticals Group plc	Dr Mark Rothera, Regional & Marketing Director, Europe Shire Human Genetic Therapies
Xenova Ltd	Alan Garmonsway, HR Director
Amura Therapeutics Ltd	Andrew Muncey, CEO

12:40 Lunch

14:00 Movers and Starters

Cambridge contimues to build a global reputation for innovative biotechnology. We meet the latest companies to join the cluster and hear their aspirations for the future.

Inion Oy	Dr Auvo Kaikkonon, CEO
The British Stem Cell Registry	Dr Lidia Duncan, Managing Director
Kodak	Dr Sam Weller, European Research Director
SimuGen	Dr Quin Wills, CSO
dotmatics Ltd	Dr Stephen Gallagher, Director & CEO
Antitope Ltd	Dr Matthew Baker, CEO & CSO
Psynova	Dr Paul Rodgers, CEO
The event will also hear from the CEOs of tomorrow - student entrepreneurs.

16:00 Session ends

18:00 Partnering closes

Day Three - Friday 12 May 2006

Partnering and Bio-Concepts

08:00 Registration opens

08:30 - 16:00 Partnering
Broker new relationships and consolidate existing partnerships by pre-booking one to one meetings with other delegates at ERBI's Biopartnering Exchange.
Arranging individual meetings for biotech, pharma and VC delegates is now a key feature of our 3 day event.
Click here for full details.

09:30 - 1300 Bio-Concepts Technology Showcase
This event is a rare opportunity for you to meet representatives from the region's leading universities and research institutes, all under one roof, in one day. Attendance is free and open to everyone. Click here for more information.

16:00 Partnering closes